CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

10.1002/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C

10.1182/blood.V82.8.2568.2568

10.1056/NEJM199607113350204

10.1002/1097-0142(19910701)68:1<62::AID-CNCR2820680112>3.0.CO;2-6

10.1046/j.1365-2141.1997.d01-2083.x

10.1182/blood.V89.3.789

10.1038/bjc.1988.17

Bergsagel D.E.(1975) Plasma cell myeloma: prognostic factors and criteria of response to therapy.Cancer Therapy: Prognostic Factors and Criteria of Response(ed. by M. J. Staquet) pp.7387. Raven Press New York.

Bergsagel D.E.(1998) Chemotherapy of myeloma.Multiple Myeloma: Biology and Management(ed. by J. S. Malpas D. E. Bergsagel R. A. Kyle and K. C. Anderson) pp.269302. Oxford University Press.

10.1056/NEJM197910043011402

Bird J.M., 1993, Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence of cure in long‐term survivors, Bone Marrow Transplantation, 12, 651

Bjorkstrand B., 1995, Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation, Stem Cells, Daytona, 13, 140

Bjorkstrand B., 1995, Double high‐dose therapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma, Bone Marrow Transplantation, 15, 367

10.1111/j.1365-2141.1994.tb04986.x

10.1016/0277-5379(86)90320-2

1973, Proposed guidelines for protocol studies. II. Plasma cell myeloma, Cancer Chemotherapy Reports, 4, 145

Chronic Leukemia and Myeloma Task Force, 1968, Proposed guidelines for protocol studies. II. Plasma cell myeloma, Cancer Chemotherapy Reports, 1, 17

Cross N.C.P., 1993, Competitive polymerase chain reaction to estimate the number of bcr‐abl transcripts in chronic myeloid leukemia after bone marrow transplantation, Blood, 82, 1929, 10.1182/blood.V82.6.1929.1929

Dimopoulos M.A., 1993, Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high‐risk multiple myeloma, Blood, 82, 2324, 10.1182/blood.V82.8.2324.bloodjournal8282324

10.1016/S0140-6736(80)92941-4

10.1056/NEJM199110313251802

10.1200/JCO.1995.13.6.1312

10.1016/S0140-6736(89)91548-1

10.1182/blood.V27.3.328.328

10.1046/j.1365-2141.1997.9942643.x

Joshua D.E., 1991, Multiple myeloma: plateau phase revisited, Hematology Reviews, 5, 59

10.1001/jama.1964.03070100052010

10.1056/NEJM198006123022405

10.1016/0140-6736(92)90004-M

10.1136/bmj.308.6935.1033

Malpas J.S.(1998) Clinical presentation and diagnosis.Myeloma: Biology and Management(ed. by J. S. Malpas D. E. Bergsagel R. A. Kyle and K. C. Anderson) pp.187209. Oxford University Press.

10.1093/oxfordjournals.annonc.a057902

McLaughlin P., 1982, Myeloma protein kinetics following chemotherapy, Blood, 60, 851, 10.1182/blood.V60.4.851.851

10.1046/j.1365-2141.1996.413952.x

10.1038/bjc.1989.22

10.1016/S0140-6736(89)91549-3

10.1038/sj.bmt.1701055

10.1111/j.1365-2141.1987.tb06890.x

Vesole D.H., 1996, Autotransplants in myeloma: what have we learned?, Blood, 88, 838, 10.1182/blood.V88.3.838.838